Title | MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. |
Publication Type | Journal Article |
Year of Publication | 2015 |
Authors | Nowak DG, Cho H, Herzka T, Watrud K, DeMarco DV, M Y Wang V, Senturk S, Fellmann C, Ding D, Beinortas T, Kleinman D, Chen M, Sordella R, Wilkinson JE, Castillo-Martin M, Cordon-Cardo C, Robinson BD, Trotman LC |
Journal | Cancer Discov |
Volume | 5 |
Issue | 6 |
Pagination | 636-51 |
Date Published | 2015 Jun |
ISSN | 2159-8290 |
Keywords | Animals, Cell Communication, Cell Proliferation, Epithelium, Gene Deletion, Genes, myc, Genotype, Humans, Interleukin-6, Lung Neoplasms, Male, Mice, Mutation, Neoplasm Metastasis, Neoplasms, Phosphoprotein Phosphatases, Phosphorylation, Prostatic Neoplasms, Protein Binding, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, Signal Transduction, STAT3 Transcription Factor, Stromal Cells, Tumor Suppressor Protein p53 |
Abstract | UNLABELLED: We have recently recapitulated metastasis of human PTEN/TP53-mutant prostate cancer in the mouse using the RapidCaP system. Surprisingly, we found that this metastasis is driven by MYC, and not AKT, activation. Here, we show that cell-cell communication by IL6 drives the AKT-MYC switch through activation of the AKT-suppressing phosphatase PHLPP2, when PTEN and p53 are lost together, but not separately. IL6 then communicates a downstream program of STAT3-mediated MYC activation, which drives cell proliferation. Similarly, in tissues, peak proliferation in Pten/Trp53-mutant primary and metastatic prostate cancer does not correlate with activated AKT, but with STAT3/MYC activation instead. Mechanistically, MYC strongly activates the AKT phosphatase PHLPP2 in primary cells and prostate cancer metastasis. We show genetically that Phlpp2 is essential for dictating the proliferation of MYC-mediated AKT suppression. Collectively, our data reveal competition between two proto-oncogenes, MYC and AKT, which ensnarls the Phlpp2 gene to facilitate MYC-driven prostate cancer metastasis after loss of Pten and Trp53. SIGNIFICANCE: Our data identify IL6 detection as a potential causal biomarker for MYC-driven metastasis after loss of PTEN and p53. Second, our finding that MYC then must supersede AKT to drive cell proliferation points to MYC inhibition as a critical part of PI3K pathway therapy in lethal prostate cancer. |
DOI | 10.1158/2159-8290.CD-14-1113 |
Alternate Journal | Cancer Discov |
PubMed ID | 25829425 |
PubMed Central ID | PMC4456272 |
Grant List | CA137050 / CA / NCI NIH HHS / United States R01 CA137050 / CA / NCI NIH HHS / United States P01 CA087497 / CA / NCI NIH HHS / United States P30 CA045508 / CA / NCI NIH HHS / United States 5P30CA045508 / CA / NCI NIH HHS / United States |
Related Faculty:
Brian Robinson, M.D.